Literature DB >> 3954678

Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection.

M Sugano, Y Nakashima, T Matsushima, K Takahara, M Takasugi, A Kuroiwa, O Koide.   

Abstract

The effects of diltiazem, a calcium antagonist, on the development of atherosclerosis were studied in Japanese white rabbits. The rabbits were examined at the end of 10 weeks on the following regimens; a diet of standard pellets and daily intraperitoneal (ip) injections of saline; a diet of pellets containing 1% cholesterol and daily ip injections of saline; or a diet of pellets containing 1% cholesterol and daily ip injections of diltiazem (50 mg). The plasma total and LDL cholesterol levels for the third group were significantly lower than those of the cholesterol diet group. Macroscopically, atheromatous lesions covered 26.7% +/- 6.7% (mean +/- SE) of the intimal surface of the aorta in the second group, and 0.7% +/- 0.3% in the third group (p less than 0.005). The levels of cholesterol, calcium, and uronic acid in the aortic tissue of the second group were significantly higher than those in the third. We concluded that diltiazem administered intraperitoneally suppresses the plasma total and LDL cholesterol elevation induced by the cholesterol diet and inhibits experimentally-induced atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954678     DOI: 10.1161/01.atv.6.2.237

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  13 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

4.  Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.

Authors:  C Napoli; M Chiariello; G Palumbo; G Ambrosio
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

5.  Effects of diltiazem on suppression and regression of experimental atherosclerosis.

Authors:  M Sugano; Y Nakashima; H Tasaki; M Takasugi; A Kuroiwa; O Koide
Journal:  Br J Exp Pathol       Date:  1988-08

6.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

7.  Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade.

Authors:  A Daugherty; D L Rateri; G Schonfeld; B E Sobel
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

8.  Effects of nicorandil on cell proliferation and cholesteryl ester accumulation in arterial smooth muscle cells in culture.

Authors:  R Fujiwara; T Hayashi; Y Kutsumi; K Oida; T Tamai; T Nakai; S Miyabo
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

9.  Relationship between the cardiovascular effects and both plasma and myocardial levels of clentiazem, a new benzothiazepine calcium antagonist, in anesthetized dogs.

Authors:  V Valérie; D Louis; L Marc; G Denis; C Claude; C Gilles
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

10.  International nifedipine trial on antiatherosclerotic therapy (INTACT).

Authors:  P R Lichtlen; U Nellessen; W Rafflenbeul; S Jost; H Hecker
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.